SPTBN1

Across TCGA pan-cancer cohorts, SPTBN1 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SPTBN1 data layer compared with 28 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher SPTBN1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SPTBN1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCS, UCEC, and TGCT are the cancer types where SPTBN1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	DFS	Median	IV	0.132	0.718	.002	36	view →
UCEC	DFS	Median	All	0.800	0.615	<.001	36	view →
TGCT	DFS	Median	All	0.174	0.801	.041	6	view →
HNSC	OS	Median	IV	0.001	0.643	<.001	6	view →
LUSC	OS	Median	IV	0.001	0.651	.025	6	view →
BLCA	OS	Median	IV	0.335	0.606	.048	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SPTBN1–UCS (DFS)

Open the UCS breakdown →